You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Faron Pharmaceuticals Capital Markets Day 2024
Av Inderes
The agenda is as follows:
- Opening remarks
- Faron's strategy and key focus areas - Dr. Juho Jalkanen, MD, PhD, CEO
- BEXMAB clinical data - Dr. Mika Kontro, MD, PhD, principal investigator of the BEXMAB trial
- BEXMAB MDS market assessment - Mr. Ralph Hughes, MSc, BSc
- Faron's development plan for solid tumors - Dr. Petri Bono, MD, PhD, CMO
- Who benefits from bexmarilimab and why - Future Addressable Markets - Dr. Maija Hollmén, PhD, CSO
- Q&A session
- Closing remarks
More information regarding Faron Pharmaceuticals CMD 2024